Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
16 sept. 2024 06h05 HE
|
Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
08 juil. 2024 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
Pulmonary Fibrosis Treatment Market Research: Escalating Demand for Innovative Treatment Options Amidst Escalating Prevalence - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031
24 mai 2024 03h29 HE
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
20 mai 2024 08h45 HE
|
GRI Bio, Inc.
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30 avr. 2024 10h00 HE
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
27 nov. 2023 08h35 HE
|
GRI Bio, Inc.
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to...
Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight
30 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) | DelveInsight The overall...
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
19 oct. 2023 08h45 HE
|
GRI Bio, Inc.
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients GRI Bio on track to launch Phase 2a biomarker...
Kinarus Therapeutics Announces Personnel Change
12 juil. 2023 01h00 HE
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...